KPV
A tripeptide fragment of alpha-MSH studied in animal research; not FDA-approved.
What it is
KPV is a three-amino-acid fragment — the tail of alpha-MSH — studied in the lab for anti-inflammatory activity, notably in gut and skin models. It's one of the newer arrivals in gray-market peptide catalogs.
The research is cell and animal work, much of it on inflammatory-bowel models, some exploring oral delivery. Published controlled human trials don't exist, and no regulatory pathway has been started anywhere.
What researchers have actually studied it for
Inflammation in cell and animal models — particularly gut (colitis models) and skin; human trials have not been published.
How it works
Lysine-proline-valine — alpha-MSH's C-terminal tail, which carries the parent hormone's anti-inflammatory signaling without its pigmentation activity. Proposed actions include entering cells via peptide transporters (PepT1, enriched in inflamed gut) and damping NF-κB-driven inflammatory programs.
The molecule itself
A tripeptide — lysine-proline-valine — alpha-MSH's C-terminal tail, carrying anti-inflammatory signaling without the parent's pigmentation activity. Small enough to ride peptide transporters like PepT1, which is the basis of its gut-targeting research thread.
Where it came from
Alpha-MSH fragment mapping in the 1980s–90s identified KPV as the anti-inflammatory core; academic groups later made it a favorite tool in rodent colitis and dermatitis models, including nanoparticle oral-delivery work in the 2010s. Commercial gray-market interest is recent and runs well ahead of the science.
The timeline
1980s–90s
Alpha-MSH fragment mapping identifies KPV as the anti-inflammatory core.
2000s–10s
Rodent colitis and dermatitis studies; nanoparticle oral-delivery engineering.
2020s
Gray-market catalogs adopt it; human trials remain absent.
What the research record actually contains
- Rodent colitis studies: reduced inflammation with oral or systemic KPV.
- Skin and wound-model work in animals and cell culture.
- No published human trials of any kind.
What could change this assessment
The academic oral-delivery thread (nanoparticle gut targeting) is genuinely watchable — if it advances toward IBD trials, KPV becomes a real story. The vial market runs entirely ahead of that possibility.
What's known about risks
No human data. A benign-sounding tripeptide with zero human characterization deserves the same caution the pattern always deserves.
Where it stands legally
Never approved; research-chemical channel only.
Worth asking a licensed provider
- 1.If gut inflammation is my concern, have we done the actual work-up — and tried evaluated therapies?
- 2.Is there any human study of KPV you can point to? (There isn't — what does that imply?)
- 3.What's the plan for objectively tracking my inflammation either way?
Common claims, corrected
“It's the gut-healing peptide.”
Reality: It's a rodent-colitis-model compound with clever delivery research — 'gut-healing' in humans is a marketing tense shift from animal present to human proven.
“Being an alpha-MSH fragment makes it melanotan-like.”
Reality: It's the tail that specifically lacks pigmentation activity — same parent, opposite selling point.
KPV FAQ
What is KPV used for?
Online, it's marketed for gut and skin inflammation. In the literature, it's an animal-model compound — the human uses are marketing extrapolations from rodent colitis studies.
Is KPV safe to take?
No human safety data has been published. Small peptide, benign-sounding story, zero human characterization — the pattern deserves the same caution every time.
Is KPV related to Melanotan?
Both derive from alpha-MSH, but KPV is the non-pigmenting tail fragment studied for inflammation — same parent molecule, different fragment, different story.
What's the PepT1 connection?
PepT1, a peptide transporter enriched in inflamed intestine, can carry small peptides like KPV into cells — the mechanism behind academic gut-targeting work and the kernel of truth oral-KPV marketing stretches.
Is KPV in any human trial?
No registered human trials exist. The compound's entire file is preclinical — checkable in ninety seconds on ClinicalTrials.gov.